Synergistic anti-neoplastic effects of the metformin/hypoglycemia combination were regulated by PP2A-GSK3β-MCL-1 axis, leading to a decline in the pro-survival protein MCL-1 and reduction in tumor growth in in vitro and in vivo metastatic melanomas models [115]. This evidence concerns the gene MCL1 and neoplasm.